<DOC>
	<DOCNO>NCT00604968</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy pegylated liposomal doxorubicin ( Caelyx ) elderly patient receive first-line chemotherapy metastatic locally advanced breast cancer , amenable surgery .</brief_summary>
	<brief_title>Pegylated Liposomal Doxorubicin ( Caelyx ( R ) ) Monotherapy Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer ( Study P05059 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patients meet follow criterion eligible enrollment . Female patient histologic cytologic diagnosis breast cancer locally advance metastatic , amenable surgery . Age &gt; = 65 year . World Health Organization ( WHO ) Performance Status 0 2 Measurable disease accordance Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Patients bone metastasis also include evaluate accord WHO criterion . Patients nonmeasurable disease also include . Left ventricular ejection fraction ( LVEF ) &gt; = 50 % verify ultrasound cardiography ( UCG ) ; clinical sign heart disease . Normal organ function , except due disease involvement , however maximum deviation : Screatinine &lt; = 1.5 x upper normal limit ; Bilirubin &lt; = 2 x upper normal limit ; Alanine aminotransferase ( ALAT ) and/or aspartate aminotransferase ( ASAT ) &lt; = 3 x upper normal limit . In case liver metastasis , ALAT and/or ASAT &lt; = 5 x upper normal limit . Adequate bone marrow function , ie : Platelets &gt; = 100 x 10^9/L ; Neutrophils &gt; = 1.5 x 10^9/L ; White Blood Cell ( WBC ) &gt; = 3.0 x 10^9/L ; Hemoglobin &gt; 90 g/L . Life expectancy &gt; = 12 week . Patients receive oral write information provide write informed consent . Patients enrol follow condition apply . Previous chemotherapy metastatic disease . ( The patient may receive previous endocrine therapy singledrug Herceptin . Intrapleural intrapericardial Novantrone allow . ) Recurrence &lt; = 12 month adjuvant anthracyclinecontaining treatment and/or prior doxorubicin &gt; 300 mg/m^2 epirubicin &gt; 540 mg/m^2 . Myocardial infarction within 6 month plan inclusion . Symptomatic brain metastasis . Human Epidermal growth factor Receptor 2 ( HER2 ) positivity eligible treatment trastuzumab , estrogen receptor ( ER ) positivity eligible hormonal therapy . Allergy anthracyclines . Uncontrolled infection . Other radically treat malignancy . Other disease condition contraindicate treatment allow followup .</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>